TADA1 (transcriptional adaptor 1) functions as a core structural component of the SAGA (Spt-Ada-Gcn5 acetyltransferase) complex, a highly conserved eukaryotic co-activator involved in transcriptional regulation 1. TADA1 maintains SAGA complex structural integrity and plays critical roles in regulating transcription by RNA polymerase II, RNA splicing, and DNA repair processes 1. Mechanistically, TADA1 serves as a trans-acting regulatory factor influencing alternative splicing patterns in cancer 2, and its dysregulation affects histone modification and mRNA metabolism 3. Clinically, TADA1 has emerged as significant in cancer biology. Loss of TADA1 confers resistance to vemurafenib (RAF inhibitor) in melanoma 4 and contributes to cisplatin resistance in ovarian cancer 5. In colorectal cancer, TADA1 promotes cell migration and invasion; its inhibition by miR-7702 suppresses metastatic potential 6. Additionally, TADA1 variants have been identified as candidate genes in intellectual disability cases 7, suggesting broader neurodevelopmental significance. The identification of TADA1 across multiple cancer genome screens and as a hub protein in the USP22 interactome 3 underscores its importance as a potential therapeutic target and prognostic marker in oncology.